All In Biotech

Drug Trial Radar · NCT00236067

A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: May 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

440

Actual

Start

Oct 2004

Primary completion

Not stated

Study completion Mar 2006

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
Oct 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).

Conditions

  • Generalized Anxiety Disorder

Interventions

  • GabitrilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of symptomatology associated with Generalized Anxiety Disorder as assessed by the change from baseline to endpoint in the total score of the HAM-A scale.

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham Research Group

    Birmingham, Alabama

  • Southwestern Research Institute

    Beverly Hills, California

  • Pharmacology Research Institute

    Northridge, California

  • Pacific Clinical Research

    Orange, California

  • Carman Research

    Smyrna, Georgia

  • Hawaii Clinical Research Center

    Honolulu, Hawaii

  • Hartford Research Group

    Florence, Kentucky

  • Summit Research Network

    Okemos, Michigan

  • CNS Research Institute

    Clementon, New Jersey

  • Social Psychiatry Research Inst.

    Brooklyn, New York

  • Neurobehavioral Research, Inc.

    Lawrence, New York

  • Social Psychiatry Research Inst.

    New York, New York

  • The Medical Research Network

    New York, New York

  • Northcoast Clinical Trials

    Beachwood, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Summit Research Network

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Carolina Clinical Research Services

    Columbia, South Carolina

  • Radiant Research, Salt Lake City

    Salt Lake City, Utah

  • Comprehensive Neuroscience of Northern Virginia

    Arlington, Virginia

  • Summit Research Network

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.